Abstract
Abstract Background The pathogenesis of acute myeloid leukemia (AML) is complex and not fully understood. A variety of interleukins have been shown to regulate the survival, growth, and apoptosis of leukemia cells. The IL-17 family includes interleukin-17F [rs763780; A7488G]. The IL-17F rs763780 polymorphism inhibits the wild-type IL-17F's activity and raises tumor susceptibility contributing to the emergence of certain tumor types including AML. Objectives This work aimed to study the relation between IL-17F gene polymorphism and susceptibility to AML and evaluated IL-17 plasma levels in AML with different IL-17F genotypes. Results There was no statistically significant difference in the distribution of different IL-17F genotypes between cases and controls. While the statistical comparison between both groups showed a significant difference with p-value <0.001 regarding IL-17 plasma level being higher in the case group with cutoff value >35 ng/L. Conclusion We concluded that IL-17 gene polymorphism doesn’t increase susceptibility to AML in Egyptian adults. IL-17 plasma level is an excellent diagnostic biomarker in AML patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
